PCM
FATE icon

Prelude Capital Management’s Fate Therapeutics FATE Stock Holding History

Prelude Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,837
Closed -$507K – 1830
2021
Q2 		$507K Buy
5,837
+1,700
+41% +$137K 0.02% 934
2021
Q1 		$341K Hold
4,137
– – 0.01% 1081
2020
Q4 		$376K Sell
4,137
-13,884
-77% -$862K 0.01% 826
2020
Q3 		$720K Buy
18,021
+2,573
+17% +$89.8K 0.03% 343
2020
Q2 		$530K Buy
+15,448
New +$460K 0.03% 461

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Prelude Capital Management's FATE Position: Q3 2021 in Review

Prelude Capital Management sold out of Fate Therapeutics (FATE) in Q3 2021, closing a stake of 5,837 shares — an estimated $507K sold.

Prelude Capital Management first reported a position in FATE in Q2 2020 and held it in 5 quarters. The position peaked at $720K in Q3 2020. 265 funds tracked by Wall St. Rank hold FATE as of Q3 2021.

  • Prelude Capital Management reported no remaining Fate Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Prelude Capital Management sold 5,837 Fate Therapeutics shares in Q3 2021, an estimated $507K.
  • Prelude Capital Management first reported a position in Fate Therapeutics in Q2 2020 and held it in 5 quarters.
  • Prelude Capital Management's Fate Therapeutics position peaked at $720K in Q3 2020.
  • 265 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2021.

Based on Prelude Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.